06:30 AM EST, 12/09/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Sunday that data from two investigational studies of its drug Tecvayli in the induction and maintenance treatment of patients with newly diagnosed multiple myeloma showed "promising efficacy and a tolerable safety profile."

In all, 49 patients treated with the drug, also called, teclistamab-cqyv in combination with Darzalex Faspro, lenalidomide, and dexamethasone, or with Darzalex Faspro, bortezomib, lenalidomide, and dexamethasone as induction therapy in a phase 2 study. All patients who were evaluated after three rounds of induction therapy achieved molecular residual disease negativity, the company said.

Results from the safety run-in of a phase 3 study showed the potential of Tecvayli as a maintenance therapy following autologous stem cell transplant, the company said.

Further analysis of Tecvayli combination therapies will be evaluated in a phase 3 study now enrolling patients, the company said.

Tecvayli received 2022 US Food and Drug Administration and European Commission approval as a treatment for adult patients with relapsed or refractory multiple myeloma who have previously received three lines of therapy.

Multiple myeloma is a common and incurable blood cancer that affects cells in the bone marrow.